# Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma

> **NCT03030261** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Washington University School of Medicine** · enrollment: 25 (actual)

## Conditions studied

- Multiple Myeloma in Relapse

## Interventions

- **DRUG:** Elotuzumab
- **DRUG:** Pomalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT03030261
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-11-22
- **Primary completion:** 2022-09-29
- **Final completion:** 2027-09-26
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2026-01-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03030261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03030261, "Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma". Retrieved via AI Analytics 2026-05-20 from https://api.ai-analytics.org/clinical/NCT03030261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*